Rare Care Podcast

132: An Interview With Michelle C. Werner, CEO of Alltrna

131: An Interview With Dr. Flavia Nelson of the University of Miami on Treatment Options for NMOSD

130: An Interview With Kevin M. Flanigan, MD, Director of the Center for Gene Therapy at Nationwide Children's Hospital in Columbus, Ohio

129: An Interview With Durresamin Khan, Pakistani Mother of a Boy With Duchenne Muscular Dystrophy

128: An Interview With Jenny Huang, Mother of SMA Patient and MIT Math Whiz Benjamin Lou

127: An Interview With Omer Abdul Hamid, MD, of Nemours Children's Hospital in Orlando, Florida

126: An Interview With Pamela Gavin, New CEO of the National Organization for Rare Disorders (NORD)

125: An Interview With Patricia Weltin, Founder and CEO of Beyond The Diagnosis

125: An Interview With Sarah Glass, PhD, of the n-Lorem Foundation

124: An Interview with Dimitrios Karussis, MD, PhD, on Stem Cell Therapy for Multiple Sclerosis

123: An Interview With Mary Morlino, Patient Navigator at the Undiagnosed Diseases Network Foundation

122: An Interview WIth Tracy Sharp, a Patient With Lambert-Eaton Myasthenic Syndrome

121: An Interview With University of Pennsylvania Neurologist and CIDP Expert Chafic Karam, MD

120: An Interview with Avner Reshef, MD, Top Israeli Expert in Hereditary Angioedema

119: An Interview With Pediatric Neurologist Edward Smith, MD, on the FDA Approval of Vamorolone for Boys With Duchenne Muscular Dystrophy

118: An Interview With Sharon Hesterlee, PhD, Chief Research Officer at the Muscular Dystrophy Association

117: An Interview With Ira Walker, the Muscular Dystrophy Association's 2024 National Ambassador, About Living With Spinal Muscular Atrophy

116: An Interview With Seema Lalani, MD, Director of Project GIVE, a Pediatric Rare Disease Screening Program in the Rio Grande Valley of Texas

115: An Interview With Matt Trudeau of ITF Therapeutics, on Givinostat as a Therapy for Duchenne Muscular Dystrophy

114: An Interview With Thomas Holm Pedersen, PhD, Cofounder and CEO of Denmark's NMD Pharma